
Opinion|Videos|May 12, 2025
Key RSV Vaccines
Author(s)Adam James, PharmD
A panelist discusses how physicians can navigate respiratory syncytial virus (RSV) vaccine selection by considering patient age, pregnancy status, and seasonality, highlighting the approved indications for Arexvy and Abrysvo, including maternal immunization to protect infants through passive immunity.
Advertisement
Episodes in this series

Summary for Physicians: Key RSV Vaccines and Indications
Currently available RSV vaccines include Arexvy (GSK) and Abrysvo (Pfizer, Inc). Both are approved for adults aged 60 years and older, but Abrysvo is also indicated for pregnant individuals (32 to 36 weeks gestation) to protect infants via passive immunity. Selection depends on patient age, pregnancy status, and timing relative to the RSV season.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Early Recognition and Routine Discussion: Improving Outcomes in Tardive Dyskinesia
2
Do GLP-1 Receptor Agonists Increase the Risk of Smell and Taste Disturbances?
3
Meet the FDA’s Newly Approved OTC Sunscreen Ingredient: Bemotrizinol
4
Melatonin May Reduce Musculoskeletal Pain and Improve Sleep
5









































































































